KAT2A induced EMT in breast cancer cells by activating the transforming growth factor-β (TGF-β)/Smad pathway, and inhibition of KAT2A reduced the survival, migration, and invasion of MDA-MB-231 cells in vitro [36]. This evidence concerns the gene TGFB1 and breast carcinoma.